FDA Approved: TADLIQ — Original Application (CMP Pharma, Inc.)

View source ↗

Summary

FDA approved CMP Pharma's TadliQ (tadalafil) under Original Application NDA214522, approving its use for erectile dysfunction and benign prostatic hyperplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia
• Erectile Dysfunction

Drugs mentioned

• TADLIQ (Tadalafil)

Snippet

ORIG AP for TADLIQ (TADALAFIL)